An artificial pancreas could be on the commercial market in four years with the researchers initiating testing the experimental product on diabetes patients, claims the Juvenile Diabetes Research Foundation.

Insulin pumps manufacturing company, Animas and Johnson & Johnson announced to team up to make a so-called artificial pancreas, so as to develop a system of pumps and monitors to manage type-1 diabetes.

"This is going to be a research and development first step, toward creating an artificial pancreas", Dr. Henry Anhalt, director of medical affairs for Animas, told Reuters in a telephone interview.

This device aims to prevent life-threatening seizures that happen during low blood sugar level in the body and could eliminate the need to calculate carbohydrate intake and daily insulin shots.

The foundation is expected to pocket out a whooping $8 million over the next three years for this project, with a concentrate on first-generation system ready for regulatory review within four years.

"All the parents who wake up every single night to test their children's blood sugar, maybe this will give them the peace of mind that their child will not wake up with blood sugar that is not super low", claimed Kowalski, who has type-1 diabetes himself.